The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
An 8-week trial of 2 mg/kg/day of naltrexone (Trexan, now called ReVia) was conducted with four males with autism and two males with pervasive developmental disorders. Two dependent measures were employed: (a) direct behavioral measurement conducted by blind observers using videotape recordings of periodic learning task sessions, and (b) performance measures of the learning activity. Direct behavior measures revealed one participant's attending-to-task improved while receiving naltrexone. However, two of the participants' rates of self-injury increased, as did one of those participant's rate of aggression. Significant improvement was observed on performance measures of the learning task; however, the improved performance continued during the non-drug return to baseline for the three participants who experienced this additional condition. Discussion is provided relating these findings to previously published results....